Try as we might, we can’t cover all the biotech news out there, especially with the holiday madness only just behind us! Here’s a roundup of news that didn’t make the cut.

shutterstock_477716404

  • Merus has partnered with IRB in Barcelona to develop tumor microenvironment antibodies
  • Phenex took home a $100M milestone from Gilead for its FXR agonist results
  • Allergan is making good on its promise not to hike prices by more than 10% this year
  • Affimed has joined MD Anderson’s long list of partners in an immuno-oncology deal
  • HepaRegeniX reeled in €9M in Series A to treat chronic liver diseases with kinase inhibitors

shutterstock_536755417

  • A JNK inhibitor from Xigen is performing well in Phase II
  • Saniona‘s Tesomet is delivering positive results for type 2 diabetes in Phase II
  • AB Science stumbled upon a drug that protects muscles and nerves in amyotrophic lateral sclerosis.

shutterstock_548835523

  • Pharma started the year with a busy week, and it culminated in a suicide attempt by a Novartis exec.
  • Sanofi backed down from a patent battle with Amgen, sued Novo Nordisk, and retracted vaccine ads after a C&D from the FDA of the Philippines.
  • Medigene spun out a new daughter company in Sweden making moves in cell and immunotherapy.

Cat or Dulce de Leche?

cdjjwcpuuaan4bc


Images from Brian Lasenby, Galka, Sjstudio6, Quinn Martin / shutterstock.com

Previous post

Servier offers up to €1.7B for Dual Cancer Checkpoint Inhibitors

Next post

Stem Cell Therapy from the UK fights Cardiovascular Disease